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Anaerobes are well-established human pathogens, 
especially in hosts whose normal body defenses are 
lowered by surgery, trauma, malnutrition and malig- 
nancies. Even though the contribution of Bacteroides 
jaj$is to the composition of normal anaerobic bacterial 
microbiota of the body is relatively small, it is 
paradoxically the most common anaerobic pathogen 
encountered in major human infections, in particular 
infections involving hollow organs and soft tissues. It is 
also clinically important because of its growing rate of 
resistance to a number of available antibiotics. Periodic 
determination of susceptibility of B. fragilis would 
therefore be useful in guiding the selection of empirical 
antibiotic therapy of mixed infections involving this 
clinically important anaerobic pathogen 11,2]. 
Data generated from various nationwide surveil- 
lance studies of the susceptibility of B. f r q i l i s  to a 
variety of antibiotics in the USA [3,4], Europe [5,6] 
and Japan [7] have been published. So far, surveys of 
antibiotic susceptibility of B. frugilis have not been 
conducted in Kuwait. Because of the lack of published 
data on the efficacy of these agents against anaerobes in 
Kuwait, an evaluation of their in vitro activity against 
clinical isolates of B. f r q i l i s  was undertaken in the two 
largest hospitals in the country. 
Pure powders of the five antibiotic5 were used in 
this study: piperacillin and piperacillin/tazobactam 
(Wyeth-Ayerst, Kuwait), anioxycillin/clavulanic acid 
(SniithKline Beecham Pharm., Kuwait), meropeneni 
(Zeneca, Kuwait) and imipeneni (MSD, Kuwait). Two 
hundred and twenty-one consecutive fresh isolates of 
B.frugilis sensu strict0 were studied. They were isolated 
from intra-abdominal and pelvic abscesses (198 isolates), 
post-intra-abdominal surgical wound infections (1 5 
isolates) and blood cultures (eight isolates) over a period 
of 18 months, April 1996 to December 1997, in the 
microbiology laboratories of the two hospitals. The 
isolates were identified in our Anaerobe Research 
Laboratory by conventional methods using a battery of 
biochemical and fermentation tests and confirmed by 
the Vitek Anaerobic Card System (Bio-Merieux Vitek 
Inc., Hazelwood, MO, USA). 
Minimum inhibitory concentrations (MICs) of the 
antibiotics were determined by the agar dilution 
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method [8]. Briefly, a McFarland 0.5 standard bacterial 
suspension, checked for actual CFU/mL of B. frugilis, 
was inoculated by means of a 36-pin multi-inoculator 
(Mast Laboratories Ltd, Bootle, Merseyside, UK) onto 
brucella blood agar (BBA; supplemented with 5% lysed 
horse blood) containing serial doubling dilutions of 
the five antibiotics to give final concentrations of 
0.03-256 mg/L. The antibiotic-containing BBA plates 
were then incubated in large anaerobic jars (Oxoid 
Unipath Ltd, Basingstoke, UK) in the presence of 10% 
C 0 2  and 90% H2, at 37"C, for 48 h. A reference strain 
of B.frugilis, ATCC 25285, was used as control in each 
run, throughout the experiments. The MIC was 
defined as the lowest concentration of the antibiotics 
that inhibited visible growth of bacteria. For the overall 
susceptibility, concentrations of the antibiotic that 
inhibited 50% and 90% (MICso and MIC90) of the 
isolates were calculated. The susceptibility breakpoints 
(mg/L) were as recommended by the National Com- 
mittee for Clinical Laboratory Standards (NCCLS) [9]. 
The results, as shown in Table 1, are expressed as 
the cumulative percentages of the strains inhibited at 
the various MICs. Piperacillin/tazobactam, imipenem, 
nieropenem and amoxycillidclavulanic acid had 
excellent activities against the isolates, while the activity 
of piperacillin was not as good. Of  the 221 isolates, 
only 137 (62%) were susceptible to piperacillin. The 
respective MICsos and MICsos for the 221 isolates were 
as follows: amoxycillin/clavulanic acid, 1 and 8 mg/L; 
piperacillin/tazobactam, 2 and 16 mg/L; piperacillin, 
64 and >256 mg/L; imipenem, 1 and 4 mg/L; and 
meropenem, 0.5 and 4mg/L. As can be seen, the 
carbapenems were more active than amoxycillin/ 
clavulanic acid and piperacillin/tazobactam. Eighteen 
(8%) isolates were resistant to amoxycillidclavulanic 
acid (14 with MIC of 16 mg/L and four with MIC of 
32 mg/L). The activity of piperacillin/tazobactam was 
superior to that of piperacillin alone. All the 88 
piperacillin-resistant isolates (MICs >256 mg/L) became 
susceptible, with significantly reduced MICs, when 
tested against piperacillin/tazobactam. The MICs of 
piperacillin/tazobactam for 82 (93%) of the 88 piper- 
acillin-resistant isolates were below 32 mg/L; the 
remaining six were susceptible at an MIC of 32 mg/L, 
well below the breakpoint recommended for this 
combined agent. According to the breakpoints recom- 
mended by the NCCLS, one isolate was resistant (MIC 
16 mg/L) to imipenem and meropenem. 
This study demonstrated the in vitro superiority of 
the carbapenems over two examples of broad-spectrum 
penicdins combined with p-lactamase inhibitors. How- 
ever, going by the interpretative breakpoints recom- 
mended by the NCCLS [9], all isolates were susceptible 
to piperacillin/tazobactam and the two carbapenems. 
Eighteen (8%) of the 221 isolates were resistant (MIC 
16 mg/L) to amoxycillin/clavulanic acid. Our findings 
confirm previous reports, particularly from Japan and 
the USA, of the susceptibility of B. jugilis to this agent 
[7,10]. It is possible that a p-lactamase that is not 
inhibited by clavulanic acid, as has been described 
previously in B. frugilis homology group I1 [lo], may be 
present in these strains. The MICs of piperacillin/ 
tazobactam and amoxycillin/clavulanic acid were com- 
parable but, unlike that of amoxycillin/clavulanic acid, 
the MIC9" of piperacillidtazobactam was far below the 
recommended susceptibility breakpoint. The results 
also show that piperacillin/tazobactam was more active 
than piperacillin when tested alone; piperacillin was 
only active against 62% of the isolates. The superior 
activity of piperacillin/tazobactam against B. frugilis has 
also been reported elsewhere [7,11]. Although not 
measured in this study, it is possible that the high MIC9o 
of piperacillin may be due to hyperproduction of 
0-lactamase [lo]. Relative to their breakpoints, the 
MIC90s of piperacillin/tazobactam and the carbapenems 
were low. This observation is worthy of note when one 
or the other is being considered for possible use as 
monotherapy in infections involving B. jugilis. 
Meropenem was the most active of the five 
p-lactam antibiotics. Imipenem was almost as active as 
meropenem, with their MICsos corresponding to 
within only one doubling dilution. Four isolates (1.8%) 
Table 1 Cumulative percentages of 221 B. fragilis isolates susceptible at various M I C s  
% of isolates susceptible at MIC of: 
Antibiotics 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 >256 (mg/L)" 
Amoxycillin/clavulanate 3.8 3.8 5.7 9.4 22.6 52.8 75.5 84.9 90.6 98.1 100 8 
Piperacillin/tazobactam 1.9 1.9 11.3 22.6 22.6 46.4 49.8 67.9 83.1 94.3 100 64 
Piperacillin 0 9.4 1.9 1.9 1.9 7.6 20.8 35.8 39.6 41.5 47.2 54.7 62.0 100 64 
Imipeneni 3.8 5.7 18.9 20.8 43.4 64.2 77.4 90.6 98.1 100 8 
Breakpoint 
Meroprnem 3.8 3.8 24.5 47.2 62.3 67.9 69.8 90.6 98.1 100 8 
'Reference breakpoint (NCCLS) 
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showed decreased susceptibility to meropenem and 
imipenem, with MICs of 16 nig/L. B. frugilis strains 
resistant to imipenem because of the production 
of nietallo-p-lactamases have been reported [12,13]. 
Kecently, conjugal transfer of P-lactamase-mediated 
resistance from one B. frugilis strain to another, whose 
resistance determinant was carried on a plasmid, has 
been demonstrated in laboratory experiments [14]. It  is 
therefore important to maintain close monitoring of 
our isolates for development of resistance to imipenem 
and meropenem by periodic susceptibility testing of 
clinical isolates; this would enable us to pay attention 
to possible emergence and spread of carbapenem- 
resistant isolates. 
In conclusion, piperacilldtazobactam, imipenem, 
nieropenem and amoxycillin/clavulanic acid had excel- 
lent activities against clinical B. f r a g i h  isolates, with 
susceptibility rates, at MICW, of 100%, loo%, 100% 
and 92'34, respectively. Piperacillin alone had relatively 
poor activity, with a susceptibility rate of 62%. The 
MICs of the combination agents and carbapenems were 
far below their achievable peak serum levels in humans 
following administration of normal intravenous doses. 
Data generated by this study supported the published 
susceptibility of B. jiuglilis to piperacillin/tazobactam 
and meropenem, the two agents newly approved for 
clinical use in Kuwait. Because of their broad-spectrum 
properties and P-lactamase stability, they hold promise 
in infections involving B. jkgil ic in Kuwait. Clinical 
studies with these agents would help to define their 
usefulness as monotherapy in mixed anaerobic infections 
in our local environment. 
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